| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
5-FAM-β-Amyloid (1-42), human Tris does not target a specific receptor but rather serves as a probe for studying the β-amyloid peptide itself. The unlabeled β-amyloid (1-42) peptide is the primary component of amyloid plaques in Alzheimer's disease and is known to interact with various cellular receptors including the receptor for advanced glycation end products (RAGE), scavenger receptors, and N-methyl-D-aspartate (NMDA) receptors. The 5-FAM label enables detection and tracking of the peptide.
|
|---|---|
| ln Vitro |
In vitro, 5-FAM-β-Amyloid (1-42), human Tris is used to study amyloid aggregation kinetics and fibril formation. The 5-FAM label allows for fluorescence-based detection of aggregation using techniques such as fluorescence spectroscopy, confocal microscopy, and flow cytometry. The labeled peptide can be used to monitor the effects of potential aggregation inhibitors or modulators. The 5-FAM label does not significantly alter the aggregation properties of the peptide, making it a reliable probe for studying amyloid behavior.
|
| ln Vivo |
In vivo activity of 5-FAM-β-Amyloid (1-42), human Tris is typically assessed in animal models of Alzheimer's disease. The fluorescently labeled peptide can be administered via intracerebroventricular injection or other routes to track its distribution, clearance, and aggregation in the brain. Its fluorescence enables visualization of amyloid deposits and assessment of the effects of therapeutic interventions on amyloid pathology in living animals or ex vivo tissue sections.
|
| Enzyme Assay |
Non-cellular binding assays for 5-FAM-β-Amyloid (1-42), human Tris involve incubating the labeled peptide with various potential binding partners such as amyloid-binding proteins, lipids, or surfaces. Binding is detected by measuring changes in fluorescence intensity, anisotropy, or by using fluorescence correlation spectroscopy. The peptide's interaction with synthetic membranes or amyloid-binding dyes (e.g., Thioflavin T) can also be studied to characterize its aggregation state and binding properties.
|
| Cell Assay |
In vitro cellular experiments with 5-FAM-β-Amyloid (1-42), human Tris are performed by treating cultured neurons or other cell types with the labeled peptide. Cellular uptake, intracellular localization, and cytotoxicity are monitored using fluorescence microscopy and flow cytometry. The peptide can be used to study amyloid-induced neurotoxicity, inflammatory responses, and the effects of potential neuroprotective compounds. The 5-FAM label enables real-time tracking of peptide internalization and distribution.
|
| Animal Protocol |
In vivo animal experiments using 5-FAM-β-Amyloid (1-42), human Tris involve administration of the labeled peptide into the brains of rodents via stereotaxic injection. The distribution and aggregation of the peptide in the brain are monitored using in vivo imaging techniques such as fluorescence microscopy of brain sections or, in some cases, in vivo fluorescence imaging. The compound can be used to evaluate the efficacy of therapeutic strategies aimed at reducing amyloid accumulation or toxicity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5-FAM-β-Amyloid (1-42), human Tris are not well characterized as the compound is a research tool rather than a therapeutic agent. The peptide is typically stored as a powder at -20°C for up to 3 years and in solution at -80°C for 1 year. It should be kept away from moisture. For aggregation studies, the peptide is first dissolved in cold hexafluoroisopropanol (HFIP) to ensure monomerization, then the HFIP is evaporated, and the peptide film is dissolved in DMSO.
|
| Toxicity/Toxicokinetics |
Toxicity data for 5-FAM-β-Amyloid (1-42), human Tris are derived from studies of the unlabeled β-amyloid peptide. The peptide is known to be neurotoxic and can induce oxidative stress, inflammation, and apoptosis in neuronal cells. Appropriate safety precautions should be taken when handling the compound, including the use of personal protective equipment. The compound is for research use only and not for human therapeutic applications.
|
| Additional Infomation |
5-FAM-β-Amyloid (1-42), human Tris is also known as 5-FAM-Amyloid β-peptide (1-42) (human) Tris. The 5-FAM label provides a fluorescent tag for detection. The peptide is used in Alzheimer's disease research to study amyloid aggregation and pathology. Detailed protocols for peptide handling and aggregation studies are available from the supplier. The compound is for research use only.
|
| Molecular Formula |
C224H321N55O66S.XC4H11NO3
|
|---|---|
| Molecular Weight |
4872.34 (free base)
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
